LJ-4517

• Description:

  LJ-4517 is a potent A2AAR antagonist, with a Ki of 18.3 nM. LJ-4517 is potent in displacing the binding of [3H]ZM241385 (HY-19532) at WT A2AAR[1]. LJ-4517 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

• UNSPSC:

  12352005

• Target:

  Adenosine Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/lj-4517.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O[C@H]1[C@H](N2C(C3=CC=CS3)=NC4=C(N)N=C(C#CCCCC)N=C24)OC[C@H]1O

• Molecular Formula:

  C19H21N5O3S

• Molecular Weight:

  399.47

• References & Citations:

  [1]Shiriaeva A, et al. GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A2A Adenosine Receptor. J Med Chem. 2022 Aug 17.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Adenosine A2A receptor (A2AR)

• CAS Number:

  2988849-20-1